Dennis Michael Lambert
25Patents
14h-index
14Co-inventors
70Inventor score
Filing activity: Jun 7, 1994 → Jan 24, 2003
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6017536A | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities | Chemistry; Metallurgy | 46 | Expired |
| US6060065A | Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission | Emerging Cross-Sectional Technologies | 36 | Expired |
| US6013263A | Measles virus peptides with antifusogenic and antiviral activities | Emerging Cross-Sectional Technologies | 31 | Expired |
| US6258782A | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 30 | Expired |
| US6068973A | Methods for inhibition of membrane fusion-associated events, including influenza virus | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6228983A | Human respiratory syncytial virus peptides with antifusogenic and antiviral activities | Emerging Cross-Sectional Technologies | 27 | Expired |
| US6475491B1 | Treatment of HIV and other viral infections using combinatorial therapy | Chemistry; Metallurgy | 23 | Expired |
| US6811541B2 | Traction device | Human Necessities | 22 | Expired |
| US6348568B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 22 | Expired |
| US6518013B1 | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission | Chemistry; Metallurgy | 19 | Expired |
| US6656906B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Emerging Cross-Sectional Technologies | 19 | Expired |
| US6054265A | Screening assays for compounds that inhibit membrane fusion-associated events | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6479055B1 | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6093794A | Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6562787B1 | Hybrid polypeptides with enhanced pharmacokinetic properties | Chemistry; Metallurgy | 8 | Expired |
| US6861059B2 | Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations | Chemistry; Metallurgy | 8 | Expired |
| US7122190B2 | Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids | Emerging Cross-Sectional Technologies | 5 | Expired |
| US6440656B1 | Methods for the inhibition of respiratory syncytial virus transmission | Emerging Cross-Sectional Technologies | 5 | Expired |
| US6623741B1 | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission | Chemistry; Metallurgy | 3 | Expired |
| US6333395A | Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7794725B1 | Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7514397B1 | Methods for inhibition of membrane-fusion-associated events, including Hepatitis B virus transmission | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6951717B1 | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6020459A | Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains | General | 1 | Revoked |
| US7297784B2 | DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.